H.C. Wainwright raised the firm’s price target on Nektar (NKTR) to $185 from $165 and keeps a Buy rating on the shares after the company reported “strong” 16-week treatment extension data from the ongoing Phase 2b REZOLVE-AA study. These “compelling results” could help significantly overcome investors’ skepticism and further solidify rezpeg’s potential in alopecia areata, the analyst contends.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Morning Movers: Energy stocks higher amid U.S.-Iran tensions
- Nektar Reports Strong Phase 2b Data in Alopecia Areata
- Nektar reports new results from Phase 2b REZOLVE-AA study
- Citi opens ‘upside 30-day catalyst watch’ on Nektar into data
- Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential